Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer
Lung Cancer
About this trial
This is an interventional treatment trial for Lung Cancer focused on measuring stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non-small cell lung cancer Stage IIIA/B disease No malignant pleural effusions Minimal residual disease after one or a combination of the following: Incomplete surgical resection i.e., macroscopic residual disease at completion of surgery Radical radiotherapy with no evidence of disease progression at entry Documented complete or partial tumor response following at least 2 courses of cytotoxic chemotherapy No evidence of disease progression during or following prior therapy PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic: Absolute neutrophil count greater than 500/mm3 Platelet count greater than 50,000/mm3 Hepatic: Bilirubin less than 2.0 times upper limit of normal (ULN) AST/ALT no greater than 3.0 times ULN Renal: Creatinine no greater than 1.5 times ULN Other: No acute illness within 1 week of start of study No other illness that would significantly interfere with study outcome No major medical illness that precludes prolonged marimastat administration No second malignancy within 5 years except: Adequately treated basal cell carcinoma of the skin In situ carcinoma of the cervix Not pregnant or nursing Medically approved method of contraception required of fertile women Willing and able to tolerate and comply with study requirements PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics No prior marimastat, batimastat, bleomycin, or busulphan No more than 1 cytotoxic chemotherapy regimen for non-small cell lung cancer Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: See Disease Characteristics Other: At least 4 weeks since any investigational drug therapies
Sites / Locations
- Comprehensive Cancer Institute of Huntsville
- Hematology Associates, Ltd.
- Marin Cancer Institute
- Scripps Clinic
- Scripps Memorial Hospital Stevens Cancer Center
- USC/Norris Comprehensive Cancer Center
- St. Joseph Hospital - Orange
- John Wayne Cancer Institute
- Kaiser Permanente Medical Center - Vallejo
- Rocky Mountain Cancer Center
- University of Colorado Cancer Center
- University of Connecticut Health Center
- Vincent T. Lombardi Cancer Research Center, Georgetown University
- Comprehensive Cancer Center at JFK Medical Center
- Radiation Therapy Associates - Fort Myers
- Oncology-Hematology Group of South Florida
- Bay Area Oncology, MD'S, PA
- Rush-Presbyterian-St. Luke's Medical Center
- University of Chicago Cancer Research Center
- Community Hospitals of Indianapolis - Regional Cancer Center
- Memorial Hospital of South Bend
- Veterans Affairs Medical Center - Lexington
- Louisiana State University School of Medicine
- Hubert H. Humphrey Cancer Center
- St. Louis University Health Sciences Center
- Southwest Cancer Clinic
- Cancer Institute of New Jersey at Hamilton
- Beth Israel Medical Center
- Kaplan Cancer Center
- Strong Memorial Hospital of the University of Rochester
- Barrett Cancer Center, The University Hospital
- Ireland Cancer Center
- Natalie Warren Bryant Cancer Center
- Abington Memorial Hospital
- Hematology-Oncology Mawr Medical North
- Milton S. Hershey Medical Center
- University of Pennsylvania Cancer Center
- Care Group
- Allegheny University Hospitals - Graduate MCP
- University of Pittsburgh Cancer Institute
- Pittsburgh Pediatric Research, Inc.
- Roger Williams Medical Center/BUSM
- Jackson Clinic Professional Association
- Baptist Regional Cancer Center - Knoxville
- Texas Oncology PA (TOPA) at Baylor-Sammons
- University of Texas Medical Branch
- University of Texas - MD Anderson Cancer Center
- Joe Arrington Cancer Research and Treatment Center
- Ottawa Regional Cancer Center - General Division
- Toronto General Hospital